An­ti­fun­gal out, can­cer in: Rev­o­lu­tion scores $500M Sanofi deal on first on­col­o­gy pro­gram

Less than a year ago, Third Rock start­up Rev­o­lu­tion Med­i­cines shed its an­ti­fun­gal am­bi­tions and re­made it­self as an on­col­o­gy com­pa­ny. Now, the Red­wood City …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER